| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/12/2022 | 237.84% | SVB Leerink | $6 → $5 | Maintains | Outperform |
| 06/08/2022 | 440.54% | Cantor Fitzgerald | $22 → $8 | Maintains | Overweight |
| 06/07/2022 | 305.41% | B. Riley Securities | $12 → $6 | Maintains | Buy |
| 06/07/2022 | 170.27% | Chardan Capital | $11 → $4 | Maintains | Buy |
| 06/07/2022 | 305.41% | SVB Leerink | $19 → $6 | Maintains | Outperform |
| 05/13/2022 | 643.24% | Chardan Capital | $14 → $11 | Maintains | Buy |
| 05/13/2022 | 1183.78% | SVB Leerink | $20 → $19 | Maintains | Outperform |
| 03/30/2022 | 1251.35% | SVB Leerink | $24 → $20 | Maintains | Outperform |
| 03/30/2022 | 1791.89% | HC Wainwright & Co. | $25 → $28 | Maintains | Buy |
| 01/14/2022 | 1589.19% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 12/23/2021 | 1589.19% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 11/01/2021 | 1521.62% | SVB Leerink | → $24 | Initiates Coverage On | → Outperform |
| 09/13/2021 | 1927.03% | Laidlaw & Co. | → $30 | Initiates Coverage On | → Buy |
| 08/25/2021 | 1656.76% | B. Riley Securities | → $26 | Initiates Coverage On | → Buy |
| 08/13/2021 | 1927.03% | Chardan Capital | $33 → $30 | Maintains | Buy |
| 01/06/2021 | 2129.73% | Chardan Capital | → $33 | Initiates Coverage On | → Buy |
Vincerx Pharma Questions & Answers
The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by SVB Leerink on August 12, 2022. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 237.84% upside). 100 analyst firms have reported ratings in the last year.
The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by SVB Leerink, and Vincerx Pharma maintained their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on August 12, 2022 so you should expect the next rating to be made available sometime around August 12, 2023.
While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a maintained with a price target of $6.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $1.48, which is out of the analyst's predicted range.